A5040750006- SARS-CoV-2 and COVID-19 Research
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Parkinson's Disease Mechanisms and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Nuclear Structure and Function
- Botulinum Toxin and Related Neurological Disorders
- Neurological disorders and treatments
- Vaccine Coverage and Hesitancy
- RNA Research and Splicing
- Influenza Virus Research Studies
- Cellular transport and secretion
- Cancer-related Molecular Pathways
- Virology and Viral Diseases
- Genetic Neurodegenerative Diseases
Adimab (United States)
2022-2024
University of Copenhagen
2020-2024
Copenhagen University Hospital
2021
Centre Hospitalier de l’Université de Montréal
2019
Abstract The rapid development of a SARS-CoV-2 vaccine is global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) spike protein. RBD antigens are displayed on AP205 CLPs through split-protein Tag/Catcher, ensuring unidirectional and high-density display RBD. Both soluble recombinant bind ACE2 receptor with nanomolar affinity. Mice vaccinated or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. RBD-CLP induce higher...
Understanding the longitudinal dynamics of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform development next-generation vaccines. Here, we track SARS-CoV-2 receptor binding domain (RBD)-specific responses up to six months Omicron BA.1 in mRNA-vaccinated individuals. Cross-reactive serum neutralizing and memory B cell (MBC) decline by two- four-fold through study period. Breakthrough elicits minimal de novo BA.1-specific but drives affinity maturation...
Capsid virus-like particles (cVLP) have proven safe and immunogenic can be a versatile platform to counter pandemics. We aimed clinically test modular cVLP COVID-19 vaccine in individuals who were naive SARS-CoV-2.In this phase 1, single-centre, dose-escalation, adjuvant-selection, open-label clinical trial, we recruited participants at the Radboud University Medical Center Nijmegen, Netherlands, sequentially assigned them seven groups. Eligible healthy, aged 18-55 years, tested negative for...
Abstract Ran is a nucleocytoplasmic shuttle protein that involved in cell cycle regulation, nuclear-cytoplasmic transport, and transformation. plays an important role cancer survival progression. Here, we show that, addition to the localization of Ran, this GTPase specifically associated with plasma membrane/ruffles ovarian cells. depletion has drastic effect on RhoA stability inhibits activity. We further demonstrate DEDDDL domain required for interaction serine 188 RhoA, which prevents...
Understanding the evolution of antibody immunity following heterologous SAR-CoV-2 breakthrough infection will inform development next-generation vaccines. Here, we tracked SARS-CoV-2 receptor binding domain (RBD)-specific responses up to six months Omicron BA.1 in mRNA-vaccinated individuals. Cross-reactive serum neutralizing and memory B cell (MBC) declined by two- four-fold through study period. Breakthrough elicited minimal de novo Omicron-specific but drove affinity maturation...
Abstract α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the unwanted activities of these αSOs, we have raised 30 monoclonal antibodies (mAbs) against different ranging from unmodified αSOs species stabilized by lipid peroxidation products polyphenols, formed C-terminally truncated α-syn, multivalent display on capsid virus-like particles (cVLPs). While mAbs generally show...
Abstract The rapid development of a SARS-CoV-2 vaccine is global priority. Here, we developed two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) spike protein. RBD antigens were displayed on AP205 CLPs through novel split-protein Tag/Catcher ensuring unidirectional and high-density display RBD. Both soluble recombinant RBD, bound ACE2 receptor with nanomolar affinity. Mice vaccinated or CLP-displayed formulated in Squalene-Water-Emulsion. RBD-CLP...
ABSTRACT Monoclonal antibodies (mAbs) targeting the influenza hemagglutinin (HA) have potential to be used as prophylactics or templates for next-generation vaccines that provide broad protection. Here, we isolated broad, subtype-neutralizing mAbs from human B cells H1 H3 HA head well a unique mAb stem. The target previously defined lateral patch epitope on HAs and recognize 1933 2021 in addition swine H1N1 virus with pandemic potential. Using directed evolution, improved neutralization...
<title>Abstract</title> Aggregation of α-synuclein (α-syn) is critical to the development synucleinopathies such as Parkinson’s Disease (PD), yet we do not have any effective therapy against these diseases. α-syn accumulates insoluble amyloid in intracellular Lewy Bodies (LBs) but also forms soluble αSOs (αSOs) which are thought be even more cytotoxic than fibrils. We lack tools detect and block unwanted activities αSOs. To address this, raised monoclonal antibodies (mAbs) different αSOs,...